BACITRACIN
BACITRACIN
XELLIA/NOVAPLUS
Drug class
Bacitracin
Bacitracin is a specific cyclic polypeptide antibacterial agent rather than an umbrella therapeutic class, though it is commonly categorized under polypeptide antibiotics. Read more about Bacitracin
1 drugs in this class 1 manufacturers
Drugs in Bacitracin
Filter & compare in the drug finder →
Opens the drug finder with Bacitracin preselected. Add indication or manufacturer filters there.
Bacitracin is a specific cyclic polypeptide antibacterial agent rather than an umbrella therapeutic class, though it is commonly categorized under polypeptide antibiotics.
It exerts bactericidal activity against primarily Gram-positive organisms by binding to undecaprenyl pyrophosphate, which inhibits the dephosphorylation and recycling of lipid carrier molecules essential for bacterial peptidoglycan cell wall synthesis.
In human clinical practice, it is utilized almost exclusively in topical and ophthalmic formulations—either alone or co-formulated with other antimicrobials—to prevent and treat superficial skin wounds, minor burns, cuts, and external ocular bacterial infections.
Systemic administration is generally avoided due to substantial risks of nephrotoxicity.
-
nih.gov
Bacitracin is a specific cyclic polypeptide antibacterial agent rather than an umbrella therapeutic class, though it is commonly categorized under polypeptide antibiotics It exerts bactericidal activity against primarily Gram-positive organisms by binding to undecaprenyl pyrophosphate, which inhibits the dephosphorylation and recycling of lipid carrier molecules essential for bacterial peptidoglycan cell wall synthesis
-
fda.gov
Bacitracin is a specific cyclic polypeptide antibacterial agent rather than an umbrella therapeutic class, though it is commonly categorized under polypeptide antibiotics It exerts bactericidal activity against primarily Gram-positive organisms by binding to undecaprenyl pyrophosphate, which inhibits the dephosphorylation and recycling of lipid carrier molecules essential for bacterial peptidoglycan cell wall synthesis
-
nih.gov
It exerts bactericidal activity against primarily Gram-positive organisms by binding to undecaprenyl pyrophosphate, which inhibits the dephosphorylation and recycling of lipid carrier molecules essential for bacterial peptidoglycan cell wall synthesis
-
fda.gov
In human clinical practice, it is utilized almost exclusively in topical and ophthalmic formulations—either alone or co-formulated with other antimicrobials—to prevent and treat superficial skin wounds, minor burns, cuts, and external ocular bacterial infections
-
nih.gov
In human clinical practice, it is utilized almost exclusively in topical and ophthalmic formulations—either alone or co-formulated with other antimicrobials—to prevent and treat superficial skin wounds, minor burns, cuts, and external ocular bacterial infections
-
nih.gov
In human clinical practice, it is utilized almost exclusively in topical and ophthalmic formulations—either alone or co-formulated with other antimicrobials—to prevent and treat superficial skin wounds, minor burns, cuts, and external ocular bacterial infections
-
study.com
Systemic administration is generally avoided due to substantial risks of nephrotoxicity
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.